Literature DB >> 21484351

Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease.

Adriane Gröger1, Grzegorz Chadzynski, Jana Godau, Daniela Berg, Uwe Klose.   

Abstract

OBJECTIVES: To investigate the substantia nigra in patients with Parkinson's disease three-dimensional magnetic resonance spectroscopic imaging with high spatial resolution at 3 Tesla was performed. Regional variations of spectroscopic data between the rostral and caudal regions of the substantia nigra as well as the midbrain tegmentum areas were evaluated in healthy controls and patients with Parkinson's disease.
METHODS: Nine patients with Parkinson's disease and eight age- and gender-matched healthy controls were included in this study. Data were acquired by using three-dimensional magnetic resonance spectroscopic imaging measurements. The ratios between rostral and caudal voxels of the substantia nigra as well as the midbrain tegmentum areas were calculated for the main-metabolites N-acetyl aspartate, creatine, choline, and myo-inositol. Additionally, the metabolite/creatine ratios were calculated.
RESULTS: In all subjects spectra of acceptable quality could be obtained with a nominal voxel size of 0.252 ml. The calculated rostral-to-caudal ratios of the metabolites as well as of the metabolite/creatine ratios showed with exception of choline/creatine ratio significant differences between healthy controls and patients with Parkinson's disease.
CONCLUSIONS: The findings from this study indicate that regional variations in N-acetyl aspartate/creatine ratios in the regions of the substantia nigra may differentiate patients with Parkinson's disease and healthy controls.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484351     DOI: 10.1007/s00330-011-2123-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

Review 1.  In vivo imaging markers of neurodegeneration of the substantia nigra.

Authors:  Dorothee P Auer
Journal:  Exp Gerontol       Date:  2008-09-06       Impact factor: 4.032

Review 2.  Anatomy of the substantia nigra and subthalamic nucleus on MR imaging.

Authors:  L A Massey; T A Yousry
Journal:  Neuroimaging Clin N Am       Date:  2010-02       Impact factor: 2.264

3.  WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy.

Authors:  R J Ogg; P B Kingsley; J S Taylor
Journal:  J Magn Reson B       Date:  1994-05

4.  Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla.

Authors:  R J Ordidge; J M Gorell; J C Deniau; R A Knight; J A Helpern
Journal:  Magn Reson Med       Date:  1994-09       Impact factor: 4.668

5.  3D phase encoding 1H spectroscopic imaging of human brain.

Authors:  J H Duijn; G B Matson; A A Maudsley; M W Weiner
Journal:  Magn Reson Imaging       Date:  1992       Impact factor: 2.546

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells.

Authors:  A Brand; C Richter-Landsberg; D Leibfritz
Journal:  Dev Neurosci       Date:  1993       Impact factor: 2.984

8.  Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy.

Authors:  B Y Choe; J W Park; K S Lee; B C Son; M C Kim; B S Kim; T S Suh; H K Lee; K S Shinn
Journal:  Invest Radiol       Date:  1998-08       Impact factor: 6.016

9.  Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.

Authors:  Joseph O'Neill; Norbert Schuff; William J Marks; Robert Feiwell; Michael J Aminoff; Michael W Weiner
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

10.  Reproducibility of quantitative cerebral T2 relaxometry, diffusion tensor imaging, and 1H magnetic resonance spectroscopy at 3.0 Tesla.

Authors:  Jacobus F A Jansen; M Eline Kooi; Alfons G H Kessels; Klaas Nicolay; Walter H Backes
Journal:  Invest Radiol       Date:  2007-06       Impact factor: 6.016

View more
  8 in total

1.  Fully automated atlas-based method for prescribing 3D PRESS MR spectroscopic imaging: Toward robust and reproducible metabolite measurements in human brain.

Authors:  Wei Bian; Yan Li; Jason C Crane; Sarah J Nelson
Journal:  Magn Reson Med       Date:  2017-05-03       Impact factor: 4.668

2.  Proton CSI without solvent suppression with strongly reduced field gradient related sideband artifacts.

Authors:  Grzegorz L Chadzynski; Uwe Klose
Journal:  MAGMA       Date:  2012-08-29       Impact factor: 2.310

3.  MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?

Authors:  Gülin Öz
Journal:  Mov Disord       Date:  2015-07-17       Impact factor: 10.338

4.  Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.

Authors:  Wenbin Gu; Chen He; Juping Chen; Junchen Li
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

Review 5.  A review of the use of magnetic resonance imaging in Parkinson's disease.

Authors:  Nadya Pyatigorskaya; Cécile Gallea; Daniel Garcia-Lorenzo; Marie Vidailhet; Stéphane Lehericy
Journal:  Ther Adv Neurol Disord       Date:  2014-07       Impact factor: 6.570

Review 6.  [Degenerative cerebellar diseases and differential diagnoses].

Authors:  W Reith; S Roumia; P Dietrich
Journal:  Radiologe       Date:  2016-11       Impact factor: 0.635

7.  Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.

Authors:  Adriane Gröger; Rupert Kolb; Rita Schäfer; Uwe Klose
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 8.  Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?

Authors:  Rosella Ciurleo; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.